Project Grant HT94252310443

The National Institute on Aging awarded $1,212,742 to the Sloan-Kettering Institute for Cancer Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epichaperomes as a mechanism for restoring drug responsiveness in Alzheimer's disease. The research tests the hypothesis that epichaperome inhibition with PU-AD restores synaptic architecture and re-enables responsiveness to levetiracetam (LEV), a therapy whose efficacy depends on properly localized SV2A...

The National Institute of Neurological Disorders and Stroke awarded Brigham and Women's Hospital $492,250 on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to identify the palmitoyltransferase for glucocerebrosidase trafficking receptor LIMP2 and restore GBA1 function in Parkinson disease and Lewy body dementia. The research investigates palmitoylation—modification of proteins by the fatty acid palmitate—as a...

This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...

The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded a $8.231 million Cooperative Agreement to Emory University on September 1, 2026, under the Aging Research program (CFDA 93.866) to establish the TARGET-AD Consortium, a precision medicine framework for Alzheimer's disease molecular subtyping. The consortium integrates multi-omics data from brain and plasma samples and induced pluripotent stem cell models derived from the...

This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...

The National Institute on Aging awarded Alphamemory, LLC $752,027 on September 20, 2025, under the Aging Research program (CFDA 93.866) for Phase I STTR research targeting gamma-secretase substrate to achieve selective amyloid reduction in Alzheimer's disease treatment. The work comprises two aims. Aim 1 involves structure-activity relationship studies of lead compounds and lead optimization based on drug activity and in cellulo ADME characterization. Aim 2 encompasses in vivo pharmacokinetic...

The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on June 15, 2026, under the Aging Research program (CFDA 93.866) to develop gene therapy targeting non-motor defects in synucleinopathy. The project addresses gastrointestinal dysfunction in Parkinson's disease and related synucleinopathies by investigating alpha-synuclein pathology in the enteric nervous system. The research employs single-chain variable fragments (scFvs)—antibody...

The National Institute on Aging awarded The Washington University $162,000 on March 1, 2026, under the Aging Research program (CFDA 93.866) to identify and characterize new therapy targets in TDP-43 proteinopathies. The award supports research into the mechanisms by which TDP-43 mislocalization results in neuronal death and aims to discover previously unidentified therapy targets that mediate this disease process. TDP-43 pathology is observed across multiple neurodegenerative diseases...

The National Institute on Aging, part of the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $249,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate an innovative genetic platform for de-risking g-secretase modulator therapeutics in Alzheimer's disease. The award funds two primary aims. Aim 1 involves using CRISPR/Cas9 engineering and structure-informed design to generate and validate a novel...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,283,334.00 to the Morehouse School of Medicine (MSM) to develop and validate a progressive mouse model for Traumatic Brain Injury-related Alzheimer's Disease and Related Dementias (TBI-ADRD). The project aims to systematically screen mouse strains and TBI injury types to identify the optimal model for recapitulating key neuropathological, neurobiochemical, and neurocognitive features of human...